Fresenius SE & Co. KGaA (FRA:FRE) has been assigned a €89.10 ($103.60) price objective by research analysts at Berenberg Bank in a research note issued on Tuesday. The firm currently has a “buy” rating on the stock. Berenberg Bank’s price objective points to a potential upside of 31.82% from the company’s current price.

A number of other analysts have also weighed in on the stock. Deutsche Bank AG set a €85.00 ($98.84) price target on shares of Fresenius SE & Co. KGaA and gave the company a “buy” rating in a report on Friday, July 21st. Goldman Sachs Group, Inc. (The) set a €78.00 ($90.70) price target on shares of Fresenius SE & Co. KGaA and gave the company a “neutral” rating in a report on Thursday, October 5th. Commerzbank Ag set a €85.00 ($98.84) target price on shares of Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a report on Monday, September 18th. Citigroup Inc. set a €83.00 ($96.51) target price on shares of Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a report on Thursday, October 19th. Finally, UBS AG set a €74.00 ($86.05) target price on shares of Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a report on Tuesday, September 19th. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of €81.74 ($95.05).

Shares of Fresenius SE & Co. KGaA (FRA:FRE) opened at €67.59 ($78.59) on Tuesday. Fresenius SE & Co. KGaA has a fifty-two week low of €65.00 ($75.58) and a fifty-two week high of €80.00 ($93.02).

ILLEGAL ACTIVITY WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/fresenius-se-89-10-by-berenberg-bank/1701432.html.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co. KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.